While adjuvant immunotherapy and BRAF/MEK inhibitors improve the outcomes for BRAF V600-mutant stage III melanoma, comparisons of long-term survival and safety of these therapeutic modalities are currently lacking in Chinese patients. This evidence concerns the gene BRAF and melanoma.